KMT2A and neoplasm: demonstrated that shRNA mediated knockdown of Zeb1 in an MLL-AF9 driven AML model resulted in impaired tumor cell invasion in vitro and reduced in vivo infiltration into the bone marrow 1-week post-transplant (138).